Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Lymphocyte

News

SciClone Agreement With FDA On Special Protocol Assessment For Phase 3 Thymalfasin Trial In Stage IV Melanoma

Published November 17, 2008, 12:08 pm, Medical News Today

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company and the U.S. Food and Drug Administration (FDA) have reached agreement on the design of a phase 3 registration trial for thymalfasin as a potential treatment for stage IV melanoma.

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Lymphocyte Stories

From Various News Sources

SciClone Reaches Agreement With FDA on Special Protocol Assessment for ... - Genetic Engineering News
Breaking News Email Print Back Share Nov 17 2008, 3:30 AM EST SciClone Reaches Agreement With FDA on Special Protocol Assessment for Phase 3 Thymalfasin Trial in Stage IV Melanoma MARKETWIRE Nov 17, 2008 FOSTER CITY, CA MARKET WIRE SciClone ...

SciClone Reaches Agreement With FDA on Special Protocol Assessment for ... - Earthtimes
FOSTER CITY, CA -- 11/17/08 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company and the U.S. Food and Drug Administration (FDA) have reached agreement on the design of a phase 3 registration trial for thymalfasin as a ...

Related Social Bookmarks

None found at this time.